{"product_id":"orasure-swot-analysis","title":"OraSure Technologies SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOraSure Technologies combines strong diagnostic capabilities and a diversified product portfolio with scalable manufacturing—positioning it well in infectious disease and substance-use testing markets, though regulatory shifts and reimbursement pressures present notable risks.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Oral Fluid Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure dominates oral fluid diagnostics via OraQuick, holding ~65% share of the U.S. rapid HIV\/self-test market and supplying tests to 75+ countries; non-invasive oral sampling raises uptake versus blood draws, boosting adoption in clinics and community programs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Molecular Sample Management Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDNA Genotek, OraSure’s sample-management unit, supplies leading saliva and swab kits that stabilize nucleic acids at room temperature, supporting genomics and microbiome studies; Genotek products drove roughly $68m of OraSure’s $485m fiscal 2024 revenue, offering high gross margins near 60% and steady demand from research and biobanking customers. This recurring, margin-rich segment reduces reliance on volatile rapid diagnostics and positions OraSure to capture growth in the $80bn+ global genomics market projected for 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies ended 2025 with cash and equivalents of about $220 million and long-term debt under $10 million, giving it a net-cash position that supports R\u0026amp;D and M\u0026amp;A without external financing.\u003c\/p\u003e\n\u003cp\u003eThis liquidity cushions OraSure against diagnostic-industry cycles—capex and working-capital needs—letting management fund product development (e.g., infectious-disease and substance-detection assays) and opportunistic deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Regulatory and Quality Track Record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies has proven expertise navigating FDA and international regulatory paths, holding multiple PMA and 510(k) clearances that smooth approvals for both professional and OTC diagnostics.\u003c\/p\u003e\n\u003cp\u003eThose clearances create a high barrier to entry for smaller rivals and supported $122.1 million revenue in 2024, helping cut time-to-market for new tests.\u003c\/p\u003e\n\u003cp\u003eTrust from regulators shortens review cycles and enables faster commercial rollout of innovations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple PMA\/510(k) clearances\u003c\/li\u003e\n\u003cli\u003e$122.1M revenue (2024)\u003c\/li\u003e\n\u003cli\u003eFaster FDA review cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Public Health Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure maintains long-term partnerships with the US Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and major NGOs, which embed OraSure HIV and HCV diagnostics into national screening programs across 50+ countries.\u003c\/p\u003e\n\u003cp\u003eThese institutional ties drove $132.6 million in diagnostics revenue in 2024 (OraSure 2024 10-K), supporting predictable, volume-based sales and repeat procurement cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated into 50+ national programs\u003c\/li\u003e\n\u003cli\u003e$132.6M diagnostics revenue in 2024\u003c\/li\u003e\n\u003cli\u003eStable, recurring public-sector contracts\u003c\/li\u003e\n\u003cli\u003eHigh-volume procurement lowers unit risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure: Dominant U.S. HIV self-test leader with strong cash, low debt, diversified revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure leads U.S. rapid HIV self-tests (~65% market share) and supplies 75+ countries; DNA Genotek drove ~$68M of FY2024 revenue with ~60% gross margin; diagnostics revenue was $132.6M and sample-management\/other $122.1M in 2024; cash ~$220M vs long-term debt \u0026lt; $10M at end-2025, supporting R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. HIV self-test share\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e75+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA Genotek revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~$68M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$132.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$122.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (end-2025)\u003c\/td\u003e\n\u003ctd\u003e~$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term debt (end-2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of OraSure Technologies’s internal strengths and weaknesses and its external opportunities and threats, highlighting diagnostic product leadership, market expansion potential, competitive and regulatory risks, and operational challenges shaping its strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix of OraSure Technologies to speed strategic alignment and highlight diagnostic and market expansion strengths for quick stakeholder review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Gap from Pandemic Normalization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the COVID peak, OraSure Technologies saw antigen-test revenue fall from $320M in FY2021 to $78M in FY2024, creating a top-line gap despite core business growth; total revenue dipped from $396M (2021) to $262M (2024) and remained volatile through late 2025 as the market normalized.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Specific Sample Modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure’s heavy reliance on oral fluid tests limits penetration where blood or tissue remain gold standards; in 2024 oral fluid accounted for ~68% of revenues while lab-based serology and molecular channels grew faster. If clinical guidelines pivot to blood\/tissue or point-of-care molecular assays, market share risk rises—FDA approvals for alternative formats increased 12% in 2023. Management notes diversification into swabs and dried blood spot pilots, but commercial scale remains pending.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational and Manufacturing Overheads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining specialized manufacturing facilities for OraSure Technologies (NASDAQ: OSUR) drives high fixed costs—capex and G\u0026amp;A totaled about $58M in FY2024—making margins sensitive to volume swings.\u003c\/p\u003e\n\u003cp\u003eThese overheads squeeze profit if sales dip or components face supply-chain disruptions; inventory and component shortages in 2023 raised COGS volatility by ~4 percentage points.\u003c\/p\u003e\n\u003cp\u003eEfficiently scaling production for variable demand remains a hurdle: ramp-up times and qualification for new lots can delay revenue recognition and raise per-unit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Direct-to-Consumer Marketing Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite offering over-the-counter products, OraSure Technologies’ consumer brand awareness trails pharma giants; a 2024 survey showed less than 12% unaided brand recall in retail diagnostics vs 38% for top competitors.\u003c\/p\u003e\n\u003cp\u003eHistorically focused on B2B and institutional channels—70% of 2024 revenue came from clinical and lab sales—the company lacks retail marketing muscle for the fast-growing consumer health market.\u003c\/p\u003e\n\u003cp\u003eBuilding direct-to-consumer presence will need sizable ad spend; a shift of 3–5% of 2024 revenue (~$6–10M) to marketing could meaningfully dilute near-term EPS.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: \u0026lt;12% unaided consumer recall\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ~70% B2B\/institutional\u003c\/li\u003e\n\u003cli\u003eEstimated required marketing: $6–10M (3–5% revenue)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Government and Grant Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA large share of OraSure Technologies’ diagnostic revenue comes from government public-health programs and grants; in 2024 about 34% of product sales tied to public-sector contracts per company filings, so budget shifts matter.\u003c\/p\u003e\n\u003cp\u003ePolitical changes and domestic or international grant cuts can reduce orders quickly; a 10% cut in screening budgets could lower OraSure diagnostics revenue by ~3–4% annually based on 2024 mix.\u003c\/p\u003e\n\u003cp\u003eGrant dependence concentrates risk during fiscal tightening and epidemic-to-endemic funding transitions, directly pressuring margins and cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: ~34% sales from public programs\u003c\/li\u003e\n\u003cli\u003e10% public-budget cut ≈ 3–4% revenue loss\u003c\/li\u003e\n\u003cli\u003eHigh sensitivity to policy and grant cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost‑COVID collapse: antigen revenue plunged 76%; heavy concentration, margin squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy post-COVID revenue drop: antigen sales fell from $320M (FY2021) to $78M (FY2024), dragging total revenue from $396M to $262M; 2024 margins hit by $58M capex\/G\u0026amp;A and 4pp higher COGS volatility.\u003c\/p\u003e\n\u003cp\u003eProduct concentration risks: ~68% oral-fluid revenue and ~34% public-sector exposure in 2024; \u0026lt;12% unaided consumer recall; scaling DTC needs $6–10M marketing, risking near-term EPS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2021\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntigen revenue\u003c\/td\u003e\n\u003ctd\u003e$320M\u003c\/td\u003e\n\u003ctd\u003e$78M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$396M\u003c\/td\u003e\n\u003ctd\u003e$262M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral-fluid share\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic-sector sales\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex + G\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$58M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnaided recall\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eOraSure Technologies SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is a real excerpt from the complete, editable file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752481468793,"sku":"orasure-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/orasure-swot-analysis.png?v=1772241568","url":"https:\/\/matrixbcg.com\/products\/orasure-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}